Amniotic fluid and breast milk: a rationale for breast milk stem cell therapy in neonatal diseases
link.springer.com shows its articles on its own site.
Read the article on link.springer.com ↗Article · Jul 2020 · 1 min read
In brief
In brief
This review compares amniotic fluid and breast milk stem cells to establish breast milk stem cells as a promising therapeutic option for neonatal diseases. Breast milk stem cells offer advantages including anti-inflammatory properties, multilineage differentiation potential, and easy accessibility for clinical application.
Written by the GCMD Library team from the article.
Abstract
Amniotic fluid and breast milk play important roles in structural development throughout fetal growth and infancy. Given their significance in physical maturation, many studies have investigated the therapeutic and protective roles of amniotic fluid and breast milk in neonatal diseases. Of particular interest to researchers are stem cells found in the two fluids. These stem cells have been investigated due to their ability to self-replicate, differentiate, reduce tissue damage, and their expression of pluripotent markers. While amniotic fluid stem cells have received some attention regarding their ability to treat neonatal diseases, breast milk stem cells have not been investigated to the same extent given the recency of their discovery. The purpose of this review is to compare the functions of amniotic fluid, breast milk, and their stem cells to provide a rationale for the use of breast milk stem cells as a therapy for neonatal diseases. Breast milk stem cells present as an important tool for treating neonatal diseases given their ability to reduce inflammation and tissue damage, as well as their multilineage differentiation potential, easy accessibility, and ability to be used in disease modelling.